m6A-centered Drug Response Information
General Information of the Drug (ID: M6ADRUG0211)
| Name |
Oxycodone
|
||||
|---|---|---|---|---|---|
| Synonyms |
oxycodone, Dihydrone, Dihydrohydroxycodeinone, Oxycodeinone, Dihydroxycodeinone, Oxicon, Diphydrone, Eucodalum, Oxycodon, Percobarb, Oxicodona, Endone, Oxanest, Dihydro-14-hydroxycodeinone, (-)-14-Hydroxydihydrocodeinone, Oxycodonum, Oxyfast, Supendol, Xtampza, OxyIR, Ossicodone, Endine (Australia), Oxycodonum [INN-Latin], Oxicodona [INN-Spanish], 14-Hydroxydihydrocodeinone, Eubine [France], Supendol [Canada], Codeinone, dihydrohydroxy-, Avridi, Oxyneo, PTI-821, Oxycodone cii, Pancodone Retard, Apo-oxycodone CR, Codeinone, dihydro-14-hydroxy-, 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, Pancodone retard (United Kingdom), HSDB 3142, 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, EINECS 200-960-2, Pti 821, UNII-CD35PMG570, NSC 19043, NSC-19043, PF-00345439, Codeinone, 7,8-dihydro-14-hydroxy-, BRN 0043446, CD35PMG570, CHEBI:7852, IDS-NO-002, N02AA05, Oxycodeinon, DTXSID5023407, Oxycone, Eubine (France), NSC19043, Supendol (Canada), Oxycodonum (INN-Latin), Oxicodona (INN-Spanish), OXYCODONE (MART.), OXYCODONE [MART.], OXYCODONE CII (USP-RS), OXYCODONE CII [USP-RS], oxicodone, Oxycodone SR, HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE IMPURITY D (EP IMPURITY), HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE IMPURITY D [EP IMPURITY], Oxycodonum (Latin), XTAMPZAER, DTXCID903407, (5-alpha)-4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, (5alpha)-4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYLMORPHINAN-6-ONE, 200-960-2, 76-42-6, Oxycontin, Remoxy, Xtampza ER, Pavinal, oxymorphone 3-methyl ether, Oxicone, Tekodin (free base), Ossicodone [DCIT], Oxycodone [USAN:INN:BAN], Dihydrohydroxycondeinone, 14-hydroxy-3-methoxy-17-methyl-5beta-4,5-epoxymorphinan-6-one, (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one, (-)-Oxycodone, CHEMBL656, Oxycodone (USAN/INN), 4,5.alpha.-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5.alpha.)-, Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)-, OOX, OXYCODONE [INN], OXYCODONE [MI], OXYCODONE [HSDB], OXYCODONE [USAN], Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-, OXYCODONE [VANDF], OXYCODONE [WHO-DD], SCHEMBL2737, 14-cis-Hydroxydihydrocodeinone, GTPL7093, PF06, OXYCODONE [ORANGE BOOK], Codeinone,8-dihydro-14-hydroxy-, Oxycodone 0.1 mg/ml in Methanol, Oxycodone 1.0 mg/ml in Methanol, 14-hydroxy-3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one, BDBM50370595, Morphinan-6-one, 4,5-alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)-14-hydroxy-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one, DB00497, AC-16043, DB-243425, C08018, D05312, Q407535, Morphinan-6-one,5.alpha.-epoxy-14-hydroxy-3-methoxy-17-methyl-, Morphinan-6-one,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5.alpha.)-, WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ CQ JO1 P1, (5.ALPHA.)-4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYLMORPHINAN-6-ONE, 4aH-8,5-bcd]furan-5(6H)-one, 7,7a,8,9-tetrahydro-7a-hydroxy-3-methoxy-12-methyl-, (1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one, (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one
Click to Show/Hide
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C18H21NO4
|
||||
| InChI |
1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
|
||||
| InChIKey |
BRUQQQPBMZOVGD-XFKAJCMBSA-N
|
||||
| PubChem CID | |||||
| TTD Drug ID | |||||
| DrugBank ID | |||||
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Drug
| In total 4 item(s) under this drug | ||
| Crosstalk ID: M6ACROT03381 | ||
| m6A Regulator | Methyltransferase-like 3 (METTL3) | |
| m6A Target | Histone-lysine N-methyltransferase EZH2 (EZH2) | |
| Regulated Target | Histone H3 lysine 27 acetylation (H3K27ac) | |
| Crosstalk relationship | Histone modification → m6A | |
| Disease | Lung cancer | |
| Crosstalk ID: M6ACROT03394 | ||
| m6A Regulator | Methyltransferase-like 3 (METTL3) | |
| m6A Target | Histone-lysine N-methyltransferase EZH2 (EZH2) | |
| Regulated Target | Histone H3 lysine 4 monomethylation (H3K4me1) | |
| Crosstalk relationship | Histone modification → m6A | |
| Disease | Lung cancer | |
| Crosstalk ID: M6ACROT05854 | ||
| m6A Regulator | Methyltransferase-like 3 (METTL3) | |
| m6A Target | Histone-lysine N-methyltransferase EZH2 (EZH2) | |
| Epigenetic Regulator | Cysteine methyltransferase DNMT3A (DNMT3A) | |
| Regulated Target | Methyltransferase-like protein 3 (METTL3) | |
| Crosstalk relationship | DNA modification → m6A | |
| Disease | Lung cancer | |
| Crosstalk ID: M6ACROT05856 | ||
| m6A Regulator | Methyltransferase-like 3 (METTL3) | |
| m6A Target | Histone-lysine N-methyltransferase EZH2 (EZH2) | |
| Epigenetic Regulator | DNA (cytosine-5)-methyltransferase 3B (DNMT3B) | |
| Regulated Target | Methyltransferase-like protein 3 (METTL3) | |
| Crosstalk relationship | DNA modification → m6A | |
| Disease | Lung cancer | |